ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
69 Ergebnisse für "avenues" unter ETH Entrepreneurship
Densifying Switzerland: Debates and Research Avenues for an Analysi...
... Densifying Switzerland: Debates and Research Avenues for an Analysis of Spatial Planning Policy ... Densifying Switzerland: Debates and Research Avenues for an Analysis of Spatial Planning Policy ... https://www.nsl.ethz.ch/fr/densifying-switzerland-debates-and-research- avenues-for-a-spatial ... Densifying Switzerland: Debates and Research Avenues for an Analysis of Spatial Planning Policy ...
[Ind. Eng. Chem. Res.] Molecular Epitaxy on Two-Dimensional Materia...
... -- at the two-dimensional (2D) material interfaces, opens new avenues towards the integration of 2D ... -dimensional (2D) material interfaces, opens new avenues towards the integration of 2D materials with a large ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
132 Ergebnisse für "avenues" unter Somagenetix
New avenues for pastoral development in sub-Saharan Africa - Zurich...
... New avenues for pastoral development in sub-Saharan Africa Hagmann, T ; Ifejika Speranza, C (2010 ... ). New avenues for pastoral development in sub-Saharan Africa. European Journal of Development Research ... New avenues for pastoral development in sub-Saharan Africa - Zurich Open Repository and Archive ... New avenues for pastoral development in sub-Saharan Africa - Zurich Open Repository and Archive ... New avenues for pastoral development in sub-Saharan Africa - Zurich Open Repository and Archive ...
UZH - Institute for Regenerative Medicine • IREM - Rust et al: New ...
... shown in a mouse model. The study opens up new avenues for treatment. ... the University of Zurich have shown in a mouse model. The study opens up new avenues for treatment ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
73 Ergebnisse für "avenues" unter University of Zurich
UZH - Institut für Medizinische Virologie - Group Huber
... immunodeficiencies, HIV infection), which may open avenues for tailored diagnostics and improved treatment options ... immunocompromised settings (transplantation, primary immunodeficiencies, HIV infection), which may open avenues for ...
UZH - Institut für Medizinische Virologie - Group Huber
... immunodeficiencies, HIV infection), which may open avenues for tailored diagnostics and improved treatment options ... immunocompromised settings (transplantation, primary immunodeficiencies, HIV infection), which may open avenues for ...
Dualsystems Biotech AG
8952 Schlieren, Grabenstrasse 11a
+41 44 738 50 00
info@dualsystems.com
Dualsystems Biotech is a provider of proteomics services for industry and academia.
Dualsystems Biotech AG
Grabenstrasse 11a
8952 Schlieren
24 Ergebnisse für "avenues" unter Dualsystems Biotech AG
University of Manitoba – Dualsystems Biotech AG
... interest in rat primary neurons, and this has created new and exciting avenues for our research." Sari S ... receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues ...
CaptiRec Services, Ligand-receptor capture technology LRC-TriCEPS
... , and this has created new and exciting avenues for our research." Sari S. Hannila, PhD Associate Member ... interest in rat primary neurons, and this has created new and exciting avenues for our research." Sari S ... receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues ... our protein of interest in rat primary neurons, and this has created new and exciting avenues for our ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
8 Ergebnisse für "avenues" unter University Hospital Zurich, Research and Education Office
Protein conformation- focus on skin in SSc – University Hospital Zurich
... other side, this project opens new avenues in the understanding the progression of dermal or visceral ... avenues in the understanding the progression of dermal or visceral organ fibrogenesis in SSc ...
Protein conformation- focus on skin in SSc – University Hospital Zurich
... other side, this project opens new avenues in the understanding the progression of dermal or visceral ... avenues in the understanding the progression of dermal or visceral organ fibrogenesis in SSc ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
9 Ergebnisse für "avenues" unter Roche Glycart AG
Pushing beyond what’s possible
... . Believing that they’d tried all avenues, Hasane and his team were disappointed. Then one day they had the ... . Believing that they’d tried all avenues, Hasane and his team were disappointed. Then one day they had the ...
Pushing beyond what’s possible
... . Believing that they’d tried all avenues, Hasane and his team were disappointed. Then one day they had the ... . Believing that they’d tried all avenues, Hasane and his team were disappointed. Then one day they had the ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
Kuros Biosciences AG
8952 Schlieren, Wagistrasse 25
+41 (0)44 733 4747
Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
CDR-Life AG
8810 Horgen, Tödistrasse 46
CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.
CDR-Life AG
Tödistrasse 46
8810 Horgen
1 Ergebnisse für "avenues" unter CDR-Life AG
News - CDR-Life
... escape or resistance mechanisms Uncovering the long-term effects and exploring future avenues for ... escape or resistance mechanisms Uncovering the long-term effects and exploring future avenues for ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Wagistrasse 25
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Wagistrasse 25
8952 Schlieren
1 Ergebnisse für "avenues" unter CSL Vifor
CSLStatutoryAccountsfortheFullYearEnded30June2023.pdf
CSLStatutoryAccountsfortheFullYearEnded30June2023.pdf, https://investors.csl.com/pdf/e8ce8240-84d6-4fb2-bf29-c2bbd28ca50a/CSL-Statutory-Accounts-for-the-Full-Year-Ended-30-June-202.pdf, For immedi...